Pharmacokinetics of the bovine formulation of enrofloxacin (Baytril® 100) in horses

Veterinary Therapeutics

Volumn 2, Issue 2, 2001, Pages 129-134

  Boeckh, Christine ^a   Buchanan, Charles ^a   Boeckh, Albert ^b   Wilkie, Scott ^b   Davis, Cal ^a   Buchanan, Terrell ^a   Boothe, Dawn ^b  

^a Brazos Valley Equine Hospital   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENROFLOXACIN; QUINOLONE DERIVATIVE;

ANIMAL; AREA UNDER THE CURVE; ARTICLE; BACTERIUM; BLOOD; CATTLE; DRUG EFFECT; FEMALE; HALF LIFE TIME; HORSE; MALE; METABOLISM; MICROBIOLOGICAL EXAMINATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BACTERIA; CATTLE; FEMALE; FLUOROQUINOLONES; HALF-LIFE; HORSES; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 52849140732     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bertone AL, Tremaine WH, Macoris DG, et al: Effect of long-term administration of an injectable enrofloxacin solution on physical and musculoskeleta variables in adult horses. JAVMA 217(10):1514-1521, 2000.
2. Beluche LA, Bertone AL, Anderson DE, Kohn CW, Wiesbrode SE: In vitro dose-dependent effects of enrofloxacin on equine articular cartilage. Am J Vet Res 60(5):577-582, 1999.
3. Langston VC, Sedrich S, Boothe DM: Disposition of single dose oral enrofloxacin in the horse. J Vet Pharmacol Ther 19(4):316-319, 1996.
4. Bayer Corp Agricultural Division: Method for the analysis of enrofloxacin and ciprofloxacin in canine plasma. Shawnee Mission, KS; 1998.
5. Akaike H: An Information Criterion (AIC). Math Sci 14:5-9, 1976.
6. nd ed. New York: Marcel Dekker; 1982:411.
7. nd ed. Philadelphia, PA: Lea & Febiger; 1989:355-375.
8. Stegemann M: Microbiology and pharmacology of enrofloxacin in cattle. Bovine Pract 31(1):76-81, 1997.
9. Pirro F, Edinloh M, Schmeer N: Bactericidal and inhibitory activity of enrofloxacin and other fluoroquinolones in small animal pathogens. Proceedings of the Third International Symposium on Fluoroquinolones. Compend Contin Educ Pract Vet 21 (Suppl): 9-25, 1999.
10. Haines GR, Brown MP, Gronwall RR, Merritt KA. Serum concentrations and pharmacokinetics of enrofloxacin after intravenous and intragastric administration to mares. Can J Vet Res 64:171-177, 2000.
11. Cester CC, Schneider M, Totain PL: Comparative kinetics of two orally administered fluoroquinolones in dogs: Enrofloxacin versus marbofloxacin. Rev Med Vet 147(10):703-716, 1996.
12. Kung K, Riond J, Wanner M: Pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. J Vet Pharmacol Ther 16:462-468, 1993.
13. Guigere S, Sweeney RW, Belanger M: Pharmacokinetics of enrofloxacin in adult horses and concentration of the drug in serum, body fluids, and endometrial tissues after repeated intragastrically administered doses. Am J Vet Res 57(7):1025-1030, 1996.
14. Papich M: Comparison of fluoroquinolone antibacterials [abstract]. Proc ACVIM 17:53-55, 1999.
15. Pirro R, Scheer M, de Jong A: Additive in vitro activity of enrofloxacin and its main metabolite ciprofloxacin. Proc 14th Ann Cong Eur Soc Vet Dermatol, 1997.